A PHASE 1/2a STUDY of REGN7041 (ANTI-CD3 MONOCLONAL ANTIBODY) in PARTICIPANTS WITH ACTIVE NONINFECTIOUS UVEITIS AFFECTING THE POSTERIOR SEGMENT
Research Grant
Awarded By
Regeneron Pharmaceuticals, Inc.
Start Date
September 1, 2025
End Date
June 30, 2028
Awarded By
Regeneron Pharmaceuticals, Inc.
Start Date
September 1, 2025
End Date
June 30, 2028